Wall Street analysts think Facebook's cryptocurrency payments project will give the company a big boost.Marketsread more
Facebook's reported move into cryptocurrency could amount to the biggest catalyst for digital assets in their decade-long history, some crypto investors say.Bitcoinread more
The Fed is expected to cut rates multiple times, but the reason behind those cuts could have vastly different implications for the market.Marketsread more
"This is going to be the biggest thing that's happened to Facebook in years," says CNBC's Jim Cramer. "It will be vital."Investingread more
A recent Fed survey showed that workers' confidence for finding a new job after losing their current position was at 61.5% in May.Economyread more
These are the stocks posting the largest moves midday.Market Insiderread more
The red-hot market for new public companies in 2019 like Beyond Meat and Chewy could spell bad news for the stock market, Bernstein says.Marketsread more
The "captive carry flight test" evaluates the mock weapon during flight and is the Air Force's latest step amid the budding hypersonic arms race between China and Russia.Politicsread more
It's about time to write off high-growth tech stocks, Goldman warns, saying software carries the highest multiples since the tech bubble.Marketsread more
Profits for major U.S. tobacco companies could be cut in half if the FDA adopts a "maximum nicotine" rule within the next 15 years, according to analysts at Morgan Stanley.Tobaccoread more
Mursi, a top figure in the now-banned Muslim Brotherhood, had been in jail since being toppled by the military in 2013 after barely a year in power following mass protests...World Politicsread more
Amazon Business, which sells bulk items to business customers, has shelved its plan to sell and distribute pharmaceutical products after considering it last year, according to people familiar with the matter.
Instead, the company is focused on selling less sensitive medical supplies to hospitals and smaller clinics through Amazon Business — and it has found that business to be more challenging than expected.
The setback illustrates the challenges of getting into the medical supply and pharmaceutical space, even for a company as big as Amazon. Several healthcare and pharmaceutical distribution companies saw their stock take a nose dive following recent reports of Amazon potentially getting into the space, but it will likely take some time before those concerns turn into real threats.
The change in plan comes partly because Amazon has not been able to convince big hospitals to change their traditional purchasing process, which typically involves a number of middlemen and loyal relationships.
Moreover, Amazon would also need to build a more sophisticated logistics network that can handle temperature-sensitive pharmaceutical products, according to these people.
Still, Amazon hasn't completely ruled out getting into the pharma distribution space eventually. Multiple reports have speculated that the company will someday add a direct-to-consumer prescription drug business. Amazon Business could also re-consider getting into the pharma space once it gains more scale, multiple people said.
Meanwhile, the company continues to explore other healthcare projectsthrough different teams across the company, including Alexa and the secretive Grand Challenge team, sometimes referred to as "1492."
Harder than expected
Amazon has been selling medical products like glucometers, gloves and stethoscopes into medical clinics for several years. It now has the necessary licensing in 47 out of 50 states and the District of Columbia, according to its website.
But Amazon has struggled to land contracts with large hospital networks, despite convening an advisory board that includes major hospital executives, according to two people familiar. These groups of hospitals have longstanding contracts with distributors, like Cardinal Health and McKesson. Many hospitals also own a stake in entities called group purchasing organizations that negotiate on their behalf, leveraging their collective negotiating power.
In addition, Amazon isn't yet selling products considered high-risk, known as "Class III" devices. For instance, it's not selling anything that needs to be implanted into the human body and sustains life, like a pacemaker. Some large hospitals have been reluctant to move over to Amazon in part because it lacks these products.
An Amazon spokesperson told CNBC, "As we've developed Amazon Business, we've used our working-backwards methodology for consumers and applied it to the needs of business customers and sellers. One of the ways we do this is convening advisory boards from across the industry to give us feedback so we can continue innovating on behalf of customers."
The health care supply chain is well-entrenched and will be hard to break into, according to one expert. "The hospital and health care systems have entangling alliances with their existing purchasing and supply chain partners," said Tom Cassels, head of strategy and business development at Leidos Health. "It's very difficult to replicate the Amazon buying experience in healthcare," he said.
For now, the sweet spot for Amazon Business in health care is smaller practices, such as dental offices, freestanding ambulatory surgery centers and small physician practices, where the licensed providersappreciate the convenience and affordability.
Even then, several of the physicians interviewed by CNBC said they were sticking with their existing distributor for most supplies, but relying on Amazon for some items, or in emergencies.
Amazon told CNBC that it serves health practices of all sizes: "Amazon Business serves healthcare customers of all sizes, from large IDNs [integrated delivery networks, meaning systems that provide both medical services and a health insurance plan to patients] to small- and medium-sized community hospitals. We also serve customers from physician and dental offices to senior living and long-term care facilities."
No 'Cold Chain'
Another major barrier to entry has been Amazon's warehouse and logistics infrastructure, which is not set up to store and deliver temperature-sensitive pharmaceutical products.
Many biopharma companies require their products to be stored and shipped in a tightly controlled supply chain system. For example, some products have insulation and need to be stored in a warehouse that can provide an ice-cold environment.
Amazon's current logistics network doesn't offer this type of sophistication. Today, some Amazon sellers that sell temperature-sensitive products use a customized delivery process, according to several people familiar with the company.
This part of the supply chain, called "Cold Chain," would be costly to build out for Amazon.
Pharma products that require refrigerated storage and transport were worth around $283 billion as of 2017, and the segment is expected to grow 70 percent by 2021, according to Pharmaceutical Commerce.
"You can't use FedEx or UPS trucks for delivery of these products," said a seller of a health care product on Amazon, who declined to be identified out of concerns it would jeopardize his relationship with Amazon. "It would be a massive undertaking [to build the infrastructure]."
With CNBC in the U.S., CNBC in Asia Pacific, CNBC in Europe, Middle East and Africa, and CNBC World, CNBC is the recognized world leader in business news and provides real-time financial market coverage and business information to more than 409 million homes worldwide, including more than 91 million households in the United States and Canada. CNBC also provides daily business updates to 400 million households across China. The network's 15 live hours a day of business programming in North America (weekdays from 4:00 a.m. - 7:00 p.m. ET) is produced at CNBC's global headquarters in Englewood Cliffs, N.J., and includes reports from CNBC News bureaus worldwide. CNBC at night features a mix of new reality programming, CNBC's highly successful series produced exclusively for CNBC and a number of distinctive in-house documentaries.
CNBC also has a vast portfolio of digital products which deliver real-time financial market news and information across a variety of platforms including: CNBC.com; CNBC PRO, the premium, integrated desktop/mobile service that provides live access to CNBC programming, exclusive video content and global market data and analysis; a suite of CNBC mobile products including the CNBC Apps for iOS, Android and Windows devices; and additional products such as the CNBC App for the Apple Watch and Apple TV.
Members of the media can receive more information about CNBC and its programming on the NBCUniversal Media Village Web site at http://www.nbcumv.com/programming/cnbc.
For more information about NBCUniversal, please visit http://www.NBCUniversal.com.